Option Care Health, Inc. shares rise 1.43% premarket after Oculis appoints new Chief Medical Advisors.

Option Care Health, Inc. rose 1.43% in premarket trading. The company appointed Mark Kupersmith, M.D., as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and the initiation of multiple programs in neuro-ophthalmology. Additionally, Sebastian Wolf, M.D., Ph.D., was appointed as Chief Medical Advisor, Ophthalmology, due to the material advancement in retina programs with recent enrollment completion of Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema and positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis.